Alder BioPharmaceuticals® to Present at Two Upcoming May Investor Conferences
Get Alerts ALDR Hot Sheet
Join SI Premium – FREE
BOTHELL, Wash., May 14, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that members of the management team will provide a business overview and update at the 2019 RBC Capital Markets Global Healthcare Conference at 9:30 am ET on Tuesday, May 21, 2019 and at the UBS Global Healthcare Conference at 10:00 am ET on Wednesday, May 22, 2019, both in New York, NY.
The presentations will be webcast live on the Events & Presentations page of the Investors section of Alder's website at http://www.alderbio.com, or by following the links below in your web browser. An archived replay of each webcast will be available on Alder's website for at least 30 days after each live event concludes.
- RBC: http://www.veracast.com/webcasts/rbc/healthcare2019/15314267548.cfm
- UBS: https://cc.talkpoint.com/ubsx001/052019a_as/?entity=49_QLELLE8
About Alder BioPharmaceuticals, Inc.Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming migraine treatment through the discovery, development and commercialization of novel therapeutic antibodies. Alder’s lead product candidate, eptinezumab, is an investigational monoclonal antibody (mAb) delivered by infusion that inhibits the CGRP for the prevention of migraine. If approved by the U.S. Food and Drug Administration, it will be the first quarterly, anti-CGRP infusion therapy for migraine prevention. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention. For more information, please visit www.alderbio.com.
Investor Relations Contact: Michael SchaffzinStern Investor Relations, Inc.212.362.1200[email protected]
Media Contact: Ashley CadleTogoRun[email protected]310.463.0143
Source: Alder BioPharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Resumes BorgWarner (BWA) at Outperform
- Suzelle Snowden Started With One Class on the Beach 30 years ago, Now She's Running the World's Largest Fitness & Wellness Travel Empire Fit Bodies Inc and Just Signed Hyatt All Inclusive Collecti
- Grabar Law Office Investigates Claims on Behalf of Long-Term Hyliion Holdings Corp. (HYLN) Shareholders
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
UBS, RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share